Tiziana's Intranasal Foralumab Shows Disability Stabilization in SPMS Trial
Event summary
- Tiziana's intranasal foralumab demonstrated disability stabilization in 14 na-SPMS patients over a year of treatment.
- 64% of patients showed clinically meaningful fatigue improvement (≥4 points on MFIS).
- Single disability progression event observed vs. placebo/tolebrutinib arms in HERCULES trial.
- Phase 2a placebo-controlled trial (NCT06292923) ongoing for non-active SPMS.
The big picture
Tiziana's intranasal foralumab represents a novel approach to treating non-active SPMS, a form of MS with limited therapeutic options. The data suggest potential for disability stabilization and fatigue reduction, though the small sample size requires validation in larger trials. The biotech is positioning foralumab as a paradigm shift in neuroinflammatory disease treatment, competing with established players like Sanofi's tolebrutinib.
What we're watching
- Regulatory Pathway
- Whether the expanded access data will support accelerated approval given the small sample size.
- Competitive Positioning
- How foralumab's intranasal delivery differentiates it from IV-administered neuroinflammatory therapies.
- Clinical Validation
- The pace at which Phase 2a results confirm disability stabilization trends in a controlled setting.
Related topics